Bioforum acquires TechnoSTAT to bolster biometric solutions in clinical trials

ISRAEL—Bioforum the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and technology-driven solutions to the global clinical trials industry, has acquired the business assets of TechnoSTAT. 

 This acquisition marks a significant step in Bioforum’s strategy to enhance its capabilities and expand its service offerings. 

The integration of TechnoSTAT into Bioforum brings complementary expertise and resources, significantly bolstering Bioforum’s team of clinical trial subject-matter experts. 

 This move will enhance Bioforum’s industry-leading services and solutions designed to optimize and automate biometric processes.  

Furthermore, the acquisition aligns with Bioforum’s mission to provide comprehensive and advanced biometric solutions, thereby improving the overall efficiency and effectiveness of clinical trials. 

Under the terms of the agreement, TechnoSTAT’s workforce will join Bioforum, ensuring a seamless transition for TechnoSTAT customers who will now benefit from Bioforum’s extensive suite of services.  

This transition underscores Bioforum’s commitment to maintaining continuity and high-quality service for all its clients.  

Additionally, this exclusive deal is part of Bioforum’s ongoing efforts to further enrich its clinical data management, biostatistics, statistical programming, and medical writing services, as well as solutions designed to power the automation of key biometric study processes. 

These advanced solutions include Bioforum’s technology-enabled tools for visual analytics (BioGrid), SDTM conversion (JetConvert), and risk analysis and validation (Validify).  

These tools are integral to Bioforum’s strategy to provide innovative and efficient solutions to its clients, helping them transform complex clinical trial data into accurate, understandable, and actionable results. 

Speaking during the acquisition event, Amir Malka, Bioforum’s CEO and Co-Founder, noted that this acquisition would enable Bioforum to address the increasing market demand for high-quality biometrics services and solutions.  

He emphasized that these services are crucial for transforming complex clinical trial data into meaningful outcomes that can drive decision-making and enhance the success of clinical trials.  

Malka expressed his delight at welcoming TechnoSTAT to the Bioforum family, highlighting that this expansion would significantly enhance Bioforum’s talent pool and operational capabilities, thus supporting both early-stage and established companies conducting research studies. 

Tal Zuker, CEO of TechnoSTAT, echoed these sentiments, underscoring the importance of ensuring data quality, integrity, and compliance with regulatory requirements. 

She stated that these elements are essential to the success of every clinical trial and, consequently, to the health of patients. 

Zuker expressed her excitement at joining forces with Bioforum, noting that their collective strengths would provide enhanced solutions that drive value and innovation for clinical trial sponsors and the patients they serve. 

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook

Newer Post

Thumbnail for Bioforum acquires TechnoSTAT to bolster biometric solutions in clinical trials

AstraZeneca announces setback in early-stage lung cancer drug imfinzi

Older Post

Thumbnail for Bioforum acquires TechnoSTAT to bolster biometric solutions in clinical trials

Teva launches authorized generic of Victoza for diabetes type 2 treatment in US

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.